Alzheimer’s drug is one critical clinical trial away from getting approval
NEW YORK: It’s incredibly difficult to bring a new pharmaceutical drug to market – about 95% of drugs in clinical trials never get approval. For Alzheimer’s disease, that percentage changes to 99%.
